Table 3.
Risk factors for acute and chronic GVHD
| Events / Evaluable | Hazard Ratio (95% confidence interval) | P-value | |
|---|---|---|---|
| Grade II-IV acute GVHD | |||
| Age | |||
| <1 – 12 years | 46/446 | 1⋅00 | |
| 13 – 49 years | 49/377 | 1⋅39 (0⋅89 – 2⋅18) | 0⋅14 |
| Regimen intensity | 0⋅0062 | ||
| Nonmyeloablative | 7/171 | 1⋅00 | |
| Myeloablative | 51/440 | 4⋅14 (1⋅68 – 10⋅22) | 0⋅0020 |
| Reduced intensity | 37/212 | 4⋅43 (1⋅73 – 11⋅35) | 0⋅0019 |
| Donor type | <0⋅0001 | ||
| HLA-matched sibling | 32/513 | 1⋅00 | |
| Haploidentical related | 11/126 | 2⋅27 (1⋅08 – 4⋅77) | 0⋅03 |
| HLA-matched unrelated | 23/97 | 3⋅84 (2⋅22 – 6⋅63) | <0≥0001 |
| HLA-mismatched unrelated | 29/87 | 6⋅14 (3⋅66 – 10⋅28) | <0⋅0001 |
| Graft type | |||
| Bone marrow | 58/565 | 1⋅00 | 0⋅37 |
| Peripheral blood | 15/163 | 0⋅98 (0⋅50 – 1⋅91) | 0⋅95 |
| Umbilical cord blood | 22/95 | 1⋅61 (0⋅81 – 3⋅20) | 0⋅18 |
| HCT comorbidity index | |||
| 0-2 | 65/564 | 1⋅00 | |
| ≥ 3 | 30/259 | 0⋅94 (0⋅59 – 1⋅49) | 0⋅79 |
| Performance score | |||
| ≤ 80 | 22/149 | 1⋅00 | |
| 90 – 100 | 72/658 | 0⋅71 (0⋅42 –1⋅19) | 0⋅19 |
| Recipient CMV serology | |||
| Negative | 45/411 | 1⋅00 | |
| Positive | 50/412 | 1⋅19 (0⋅79 – 1⋅80) | 0⋅39 |
| Sex | |||
| Male | 45/439 | 1⋅00 | |
| Female | 50/384 | 1⋅16 (0⋅77 – 1⋅76) | 0⋅47 |
| Transplant period | |||
| 2008 – 2012 | 24/285 | 1⋅00 | |
| 2013 – 2017 | 71/538 | 1⋅74 (1⋅06 – 2⋅84) | 0⋅028 |
| Chronic GVHD | |||
| Age | |||
| <1 – 12 years | 98/491 | 1⋅00 | |
| 13 – 49 years | 92/419 | 1⋅46 (1⋅06 – 2⋅00) | 0⋅019 |
| Regimen intensity | <0⋅0001 | ||
| Nonmyeloablative | 17/181 | 1⋅00 | |
| Myeloablative | 97/478 | 2⋅82 (1⋅51 – 5⋅27) | 0⋅0012 |
| Reduced intensity | 76/250 | 4⋅00 (2⋅11 – 7⋅55) | <0⋅0001 |
| Donor type | 0⋅017 | ||
| HLA-matched sibling | 101/557 | 1⋅00 | |
| Haploidentical related | 22/137 | 1⋅75 (0⋅55 – 3⋅11) | 0⋅055 |
| HLA-matched unrelated | 37/111 | 1⋅70 (1⋅14 – 2⋅54) | 0⋅0087 |
| HLA-mismatched unrelated | 30/104 | 1⋅59 (0⋅95 – 2⋅67) | 0⋅08 |
| Graft type | |||
| Bone marrow | 146/630 | 1⋅00 | 0⋅09 |
| Peripheral blood | 20/177 | 0⋅55 (0⋅32 – 0⋅94) | 0⋅028 |
| Umbilical cord blood | 24/102 | 0⋅84 (0⋅49 – 1⋅46) | 0⋅54 |
| HCT comorbidity index | |||
| 0-2 | 135/637 | 1⋅00 | |
| ≥ 3 | 55/272 | 1⋅13 (0⋅81 – 1⋅57) | 0⋅47 |
| Performance score | |||
| ≤ 80 | 34/160 | 1⋅00 | |
| 90 – 100 | 152/731 | 0⋅86 (0⋅57 –1⋅28) | 0⋅44 |
| Recipient CMV serology | |||
| Negative | 93/454 | 1⋅00 | |
| Positive | 97/455 | 1⋅05 (0⋅79 – 1⋅40) | 0⋅74 |
| Sex | |||
| Male | 89/488 | 1⋅00 | |
| Female | 101/421 | 1⋅32 (0⋅99 – 1⋅77) | 0⋅06 |
| Transplant period | |||
| 2008 – 2012 | 76/327 | 1.00 | |
| 2013 – 2017 | 114/583 | 1.07 (0.79 – 1.46) | 0.65 |
Abbreviation:
GVHD = graft versus-host disease
HCT = hematopoietic cell transplant
CMV = cytomegalovirus